NasdaqCM - Nasdaq Real Time Price USD

Avalo Therapeutics, Inc. (AVTX)

17.92 +0.84 (+4.92%)
As of 3:45:24 PM EDT. Market Open.
Trade AVTX on Coinbase
Chart Range Bar
Advanced Chart
AlphaSpace Chart
Loading chart for AVTX
  • Previous Close 17.08
  • Open 16.78
  • Bid 17.67 x 200
  • Ask 22.98 x 100
  • Day's Range 16.71 - 18.54
  • 52 Week Range 4.50 - 24.27
  • Volume 1,494,388
  • Avg. Volume 1,724,693
  • Market Cap (intraday) 941.975M
  • Beta (5Y Monthly) 0.82
  • PE Ratio (TTM) --
  • EPS (TTM) -5.57
  • Earnings Date (est.) Aug 12, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 45.25

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

www.avalotx.com

33

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Avalo Therapeutics, Inc.

Recent News

View More

Weʼre unable to load stories right now.

View More

Performance Overview

Trailing total returns as of 6/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AVTX
1.32%
S&P 500 (^GSPC)
7.71%

1-Year Return

AVTX
274.11%
S&P 500 (^GSPC)
22.37%

3-Year Return

AVTX
98.31%
S&P 500 (^GSPC)
69.56%

5-Year Return

AVTX
99.83%
S&P 500 (^GSPC)
73.82%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -19.63M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-30M
-20M
-10M
0
 
View More

Analyst Insights

View More

Analyst Price Targets

34.00
45.25 Average
17.92 Current
60.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 6/16/2026
Analyst BTIG
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 58 -> 58
 
View More

Statistics

View More

Valuation Measures

Annual
As of 6/22/2026

  • Market Cap

    897.82M

  • Enterprise Value

    816.15M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.57k

  • Price/Book (mrq)

    13.14

  • Enterprise Value/Revenue

    13.83k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -41.50%

  • Return on Equity (ttm)

    -88.76%

  • Revenue (ttm)

    59k

  • Net Income Avi to Common (ttm)

    -84.74M

  • Diluted EPS (ttm)

    -5.57

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    81.99M

  • Total Debt/Equity (mrq)

    0.48%

  • Levered Free Cash Flow (ttm)

    -23.25M

View More

Compare

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

AVTX
Avalo Therapeutics, Inc.
17.92
+4.92%
Mkt Cap 941.975M
Industry Biotechnology

Company Insights

Fair Value

17.92 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

People Also Watch

TPST Tempest Therapeutics, Inc.
1.2600 +0.80%
 
ZVSA ZyVersa Therapeutics, Inc.
0.1650 -12.70%
 
ICU SeaStar Medical Holding Corporation
3.4850 +7.56%
 
NVOS Novo Integrated Sciences, Inc.
0.0035 +400.00%
 
RNAZ TransCode Therapeutics, Inc.
4.8550 -2.12%